The Medicare Part D program has achieved the rarest of distinctions among federal entitlement programs: it is both highly successful in its mission, and consistently comes in under budget. Over the past decade, Medicare Part D has provided better access and more affordable prescription drugs for more than 40 million American seniors – and it has done so at half its originally projected cost.

The success of Medicare Part D can be largely attributed to its private-sector model which leverages competition and innovation to reduce beneficiaries’ drug costs. As legislators struggle to find transformative solutions to our long-term health entitlement challenges, what can be learned from the Part D model, and how can the Part D program itself be protected and enhanced to ensure its sustainability?

Keynote
Senator Lindsey Graham (R-SC)

Panel
Douglas Holtz-Eakin, President, American Action Forum
Mike Mason, Vice President, Lilly Diabetes
Mike Anderson, Chief Pharmacy Officer, UnitedHealthcare
Former Senator Blanche L. Lincoln, Founder, Lincoln Policy Group
Paige Winfield Cunningham, Healthcare Reporter, Washington Post (moderator)